Select publications

Trastuzumab plus taxane and/or platinum salt regimens

Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28:38-44. Abstract

Burris III HA et al. Phase II trial of Herceptin induction followed by combination therapy with paclitaxel and carboplatin: A Minnie Pearl Research Network trial. Breast Cancer Res Treat 2000;Abstract 24.

Burstein HJ et al. Preoperative trastuzumab (T) and paclitaxel (P) for HER2 overexpressing (HER2+) stage II/III breast cancer: Clinical, pathological and serological findings. Breast Cancer Res Treat 2001;Abstract 507.

Crown JP. The platinum agents: A role in breast cancer treatment? Semin Oncol 2001;28(1 Suppl 3):28-37. Abstract

Dieras V et al. Interaction between Herceptin and taxanes. Oncology 2001;61 Suppl 2:43-9. Abstract

Loesch DM et al. Weekly Taxol (T) and carboplatin (C) regimen in patients with advanced breast cancer: A phase II study. Breast Cancer Res Treat 2000;Abstract 316.

Miller KD et al. Gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2001;15:38-40. Abstract

Nabholtz JM et al. Results of two open-label multicentre pilot phase II trials with Herceptin® in combination with docetaxel and platinum salts (cis- or carboplatin) (TCH) as therapy for advanced breast cancer in women overexpressing HER2. Breast Cancer Res Treat 2000;Abstract 327.

Perez EA et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;88(1):124-31. Abstract

Pienkowski T et al. Taxotere, cisplatin and Herceptin (TCH) in first-line HER2-positive metastatic breast cancer (MBC) patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc ASCO 2001;Abstract 2030.

Robert NJ et al. Toxicity profiles: A comparative study of Herceptin (trastuzumab) and Taxol (paclitaxel) versus Herceptin, Taxol and carboplatin in HER2-positive patients with advanced breast cancer. Breast Cancer Res Treat 2001;Abstract 529.

Schueller JJS et al. Pharmacokinetics (PK) of epirubicin (EPI) and docetaxel (DOCE) in combination with Herceptin (H) in breast cancer patients. Breast Cancer Res Treat 2001;Abstract 524.

Sledge GW et al. Pilot trial of Paclitaxel-Herceptin adjuvant therapy for early stage breast cancer (E2198). Breast Cancer Res Treat 2001;Abstract 4.

Seidman AD et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95. Abstract

Slamon DJ et al. Phase II pilot study of Herceptin combined with Taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2- neu proto-oncogene: A pilot study of the UCLA network. Proc ASCO 2001;Abstract 193.

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. Abstract

Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28(1 Suppl 3):13-9. Abstract

Winer EP, Burstein HJ. New combinations with Herceptin in metastatic breast cancer. Oncology 2001;61 Suppl 2:50-7. Abstract

Home · Search